MedTrace Logo

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

NCT03061708 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-05-20

No results posted yet for this study

Summary

Phase II trial of AZD2014 in RICTOR amplified or overexpressed GC patients as second-line chemotherapy AZD2014 50mg BD continuous schedule of a 28 day cycle

Conditions

  • Stomach Neoplasms

Interventions

DRUG

AZD2014

mTOR inhibitor

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jeeyun Lee, Md,PhD · SamsungMedicalCenter

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-11-16
Completion
2018-11-16

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061708 on ClinicalTrials.gov